Exploratory study for identifying systemic biomarkers that correlate with pain response in patients with intervertebral disc disorders

Immunologic Research

Volumn 63, Issue 1-3, 2015, Pages 170-180

  Weber, K T ^a   Satoh, Shina ^a   Alipui, D Olivier ^a   Virojanapa, Justin ^b   Levine, Mitchell ^b   Sison, Cristina ^a,b   Quraishi, Shaheda ^b   Bloom, Ona ^a,b   Chahine, Nadeen O ^a,b  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Back pain; Epidural steroid injection; Inflammation; Intervertebral disc

Indexed keywords

ALPHA2 INTERFERON; BIOLOGICAL MARKER; CHEMOKINE; CHEMOKINE MIG; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 16; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 9; METHYLPREDNISOLONE; MONOCYTE CHEMOTACTIC PROTEIN 1; STEM CELL GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; AUTACOID; CLEC11A PROTEIN, HUMAN; CYTOKINE; LECTIN; STEROID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EXPLORATORY RESEARCH; FEMALE; HUMAN; INTERVERTEBRAL DISK DEGENERATION; INTERVERTEBRAL DISK HERNIA; LIMIT OF DETECTION; LOW BACK PAIN; MALE; OSWESTRY DISABILITY INDEX; PAIN ASSESSMENT; PAIN NUMERICAL RATING SCALE; PILOT STUDY; PRIORITY JOURNAL; RATING SCALE; TREATMENT RESPONSE; VERTEBRAL CANAL STENOSIS; AGED; BLOOD; EPIDURAL DRUG ADMINISTRATION; HEMATOPOIESIS; INTERVERTEBRAL DISK; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); NEURODEGENERATIVE DISEASES; PAIN; PATHOLOGY; SPINAL STENOSIS;

ADULT; AGED; BIOMARKERS; CYTOKINES; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; INFLAMMATION MEDIATORS; INJECTIONS, EPIDURAL; INTERVERTEBRAL DISC; LECTINS, C-TYPE; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NEURODEGENERATIVE DISEASES; PAIN; SPINAL STENOSIS; STEROIDS;

EID: 84947485753     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-015-8709-2     Document Type: Article

References (64)

1. Manchikanti L, et al. Epidemiology of low back pain in adults. Neuromodulation. 2014;17(Suppl 2):3–10.
2. Deyo RA, Tsui-Wu YJ. Descriptive epidemiology of low-back pain and its related medical care in the United States. Spine (Phila Pa 1976). 1987;12(3):264–8.
3. Croft PR, et al. Outcome of low back pain in general practice: a prospective study. BMJ. 1998;316(7141):1356–9.
4. Frymoyer JW, Cats-Baril WL. An overview of the incidences and costs of low back pain. Orthop Clin North Am. 1991;22(2):263–71.
5. Arden NK, et al. A multicentre randomized controlled trial of epidural corticosteroid injections for sciatica: the WEST study. Rheumatology (Oxford). 2005;44(11):1399–406.
6. Pinto RZ, et al. Epidural corticosteroid injections in the management of sciatica: a systematic review and meta-analysis. Ann Intern Med. 2012;157(12):865–77.
7. Cohen SP, et al. Epidural steroid injections compared with gabapentin for lumbosacral radicular pain: multicenter randomized double blind comparative efficacy study. BMJ. 2015;350:h1748.
8. McLain RF, Kapural L, Mekhail NA. Epidural steroid therapy for back and leg pain: mechanisms of action and efficacy. Spine J. 2005;5(2):191–201.
9. Cannon DT, Aprill CN (2000), Lumbosacral epidural steroid injections. Arch Phys Med Rehabil, 81(3 Suppl 1): S87–S98; quiz S99–S100.
10. Bender R, Lange S. Adjusting for multiple testing—when and how? J Clin Epidemiol. 2001;54(4):343–9.
11. Sainani KL. The problem of multiple testing. PM R. 2009;1(12):1098–103.
12. Stein A, et al. Pilot study: elevated circulating levels of the proinflammatory cytokine macrophage migration inhibitory factor in patients with chronic spinal cord injury. Arch Phys Med Rehabil. 2013;94(8):1498–507.
13. Carnahan JF, Patel DR, Miller JA. Stem cell factor is a neurotrophic factor for neural crest-derived chick sensory neurons. J Neurosci. 1994;14(3 Pt 2):1433–40.
14. Hirata T, et al. Stem cell factor induces outgrowth of c-kit-positive neurites and supports the survival of c-kit-positive neurons in dorsal root ganglia of mouse embryos. Development. 1993;119(1):49–56.
15. Hirata T, et al. Characterization of c-kit-positive neurons in the dorsal root ganglion of mouse. Brain Res Dev Brain Res. 1995;85(2):201–11.
16. Takagi K, et al. Involvement of stem cell factor and its receptor tyrosine kinase c-kit in pain regulation. Neuroscience. 2008;153(4):1278–88.
17. Milenkovic N, et al. Nociceptive tuning by stem cell factor/c-Kit signaling. Neuron. 2007;56(5):893–906.
18. Reyes-Vazquez C, Prieto-Gomez B, Dafny N. Interferon modulates central nervous system function. Brain Res. 2012;1442:76–89.
19. Besedovsky HO, del Rey A. Introduction: immune-neuroendocrine network. Front Horm Res. 2002;29:1–14.
20. Jiang CL, et al. Analgesic effect of interferon-alpha via mu opioid receptor in the rat. Neurochem Int. 2000;36(3):193–6.
21. Wang YX, et al. Distinct domains of IFNalpha mediate immune and analgesic effects respectively. J Neuroimmunol. 2000;108(1–2):64–7.
22. Wang JY, et al. Mu- but not delta- and kappa-opioid receptor mediates the nucleus submedius interferon-alpha-evoked antinociception in the rat. Neurosci Lett. 2006;397(3):254–8.
23. Cuellar JM, et al. Cytokine evaluation in individuals with low back pain using discographic lavage. Spine J. 2010;10(3):212–8.
24. Scuderi GJ, et al. Epidural interferon gamma-immunoreactivity: a biomarker for lumbar nerve root irritation. Spine (Phila Pa 1976). 2009;34(21):2311–7.
25. Thacker MA, et al. Pathophysiology of peripheral neuropathic pain: immune cells and molecules. Anesth Analg. 2007;105(3):838–47.
26. Risbud MV, Shapiro IM. Role of cytokines in intervertebral disc degeneration: pain and disc content. Nat Rev Rheumatol. 2014;10(1):44–56.
27. Burke JG, et al. Spontaneous production of monocyte chemoattractant protein-1 and interleukin-8 by the human lumbar intervertebral disc. Spine (Phila Pa 1976). 2002;27(13):1402–7.
28. Gruber HE, et al. Proinflammatory cytokines modulate the chemokine CCL2 (MCP-1) in human annulus cells in vitro: CCL2 expression and production. Exp Mol Pathol. 2015;98(1):102–5.
29. Parkitny L, et al. Inflammation in complex regional pain syndrome: a systematic review and meta-analysis. Neurology. 2013;80(1):106–17.
30. Romero-Sanchez C, et al. Serum monocyte chemotactic protein-1 concentrations distinguish patients with ankylosing spondylitis from patients with mechanical low back pain. J Spinal Disord Tech. 2011;24(3):202–7.
31. Kang JD, et al. Herniated lumbar intervertebral discs spontaneously produce matrix metalloproteinases, nitric oxide, interleukin-6, and prostaglandin E2. Spine (Phila Pa 1976). 1996;21(3):271–7.
32. Studer RK, et al. Human nucleus pulposus cells react to IL-6: independent actions and amplification of response to IL-1 and TNF-alpha. Spine (Phila Pa 1976). 2011;36(8):593–9.
33. Murata Y, et al. Local application of interleukin-6 to the dorsal root ganglion induces tumor necrosis factor-alpha in the dorsal root ganglion and results in apoptosis of the dorsal root ganglion cells. Spine (Phila Pa 1976). 2011;36(12):926–32.
34. Wei XH, et al. The up-regulation of IL-6 in DRG and spinal dorsal horn contributes to neuropathic pain following L5 ventral root transection. Exp Neurol. 2013;241:159–68.
35. Weber K, et al. (2015) Serum levels of the pro-Inflammatory cytokines IL-6 and TNF-alpha vary based on diagnoses in individuals with low back pain. Arthritis Res Ther (in review).
36. Pedersen LM, et al. Serum levels of the pro-inflammatory interleukins 6 (IL-6) and -8 (IL-8) in patients with lumbar radicular pain due to disc herniation: A 12-month prospective study. Brain Behav Immun. 2015;46:132–6.
37. Schistad EI, et al. Association between baseline IL-6 and 1-year recovery in lumbar radicular pain. Eur J Pain. 2014;18(10):1394–401.
38. Sowa GA, et al. Associations between serum biomarkers and pain and pain-related function in older adults with low back pain: a pilot study. J Am Geriatr Soc. 2014;62(11):2047–55.
39. Shamji MF, et al. Proinflammatory cytokine expression profile in degenerated and herniated human intervertebral disc tissues. Arthritis Rheum. 2010;62(7):1974–82.
40. Gabr MA, et al. Interleukin-17 synergizes with IFNgamma or TNFalpha to promote inflammatory mediator release and intercellular adhesion molecule-1 (ICAM-1) expression in human intervertebral disc cells. J Orthop Res. 2011;29(1):1–7.
41. Gruber HE, et al. Increased IL-17 expression in degenerated human discs and increased production in cultured annulus cells exposed to IL-1ss and TNF-alpha. Biotech Histochem. 2013;88(6):302–10.
42. Tian P, et al. Role of interleukin-17 in chondrocytes of herniated intervertebral lumbar discs. Exp Ther Med. 2015;10(1):81–7.
43. Friedly JL, et al. A randomized trial of epidural glucocorticoid injections for spinal stenosis. N Engl J Med. 2014;371(1):11–21.
44. Johnsson KE, Rosen I, Uden A. The natural course of lumbar spinal stenosis. Clin Orthop Relat Res. 1992;279:82–6.
45. Zou F, et al. Efficacy of intradiscal hepatocyte growth factor injection for the treatment of intervertebral disc degeneration. Mol Med Rep. 2013;8(1):118–22.
46. Murakami K, et al. Vein wrapping for chronic nerve constriction injury in a rat model: study showing increases in VEGF and HGF production and prevention of pain-associated behaviors and nerve damage. J Bone Joint Surg Am. 2014;96(10):859–67.
47. Gong R, et al. Hepatocyte growth factor ameliorates renal interstitial inflammation in rat remnant kidney by modulating tubular expression of macrophage chemoattractant protein-1 and RANTES. J Am Soc Nephrol. 2004;15(11):2868–81.
48. Bendinelli P, et al. Molecular basis of anti-inflammatory action of platelet-rich plasma on human chondrocytes: mechanisms of NF-kappaB inhibition via HGF. J Cell Physiol. 2010;225(3):757–66.
49. Zhang J, et al. HGF mediates the anti-inflammatory effects of PRP on injured tendons. PLoS ONE. 2013;8(6):e67303.
50. Ajroud-Driss S, et al. Phase 1/2 open-label dose-escalation study of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with painful diabetic peripheral neuropathy. Mol Ther. 2013;21(6):1279–86.
51. Karamouzian S, et al. Frequency of lumbar intervertebral disc calcification and angiogenesis, and their correlation with clinical, surgical, and magnetic resonance imaging findings. Spine (Phila Pa 1976). 2010;35(8):881–6.
52. Backonja MM, et al. Altered cytokine levels in the blood and cerebrospinal fluid of chronic pain patients. J Neuroimmunol. 2008;195(1–2):157–63.
53. Kosek E, et al. Evidence of different mediators of central inflammation in dysfunctional and inflammatory pain–interleukin-8 in fibromyalgia and interleukin-1 beta in rheumatoid arthritis. J Neuroimmunol. 2015;280:49–55.
54. Lee AS, et al. A current review of molecular mechanisms regarding osteoarthritis and pain. Gene. 2013;527(2):440–7.
55. Lenz M, et al. Local cytokine changes in complex regional pain syndrome type I (CRPS I) resolve after 6 months. Pain. 2013;154(10):2142–9.
56. Lampa J, et al. Peripheral inflammatory disease associated with centrally activated IL-1 system in humans and mice. Proc Natl Acad Sci USA. 2012;109(31):12728–33.
57. de Goeij M, et al. Systemic inflammation decreases pain threshold in humans in vivo. PLoS ONE. 2013;8(12):e84159.
58. Hurme M, Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol. 1998;28(8):2598–602.
59. Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 2002;13(4–5):323–40.
60. Lin WP, et al. Interleukin-10 promoter polymorphisms associated with susceptibility to lumbar disc degeneration in a Chinese cohort. Genet Mol Res. 2011;10(3):1719–27.
61. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008;8(7):533–44.
62. Cook AD, et al. Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res. 2001;3(5):293–8.
63. Cook AD, et al. Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development. Arthritis Res Ther. 2012;14(5):R199.
64. Cuellar JM, et al. (2013) Does a fibronectin and aggrecan complex play a role in painful vertebral disks? PM R, 5(4): 297–302; quiz 302.